UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Treatment of estrogen receptor-positive breast cancer

Current medicinal chemistry, 2013-02, Vol.20 (5), p.596-604

2013

Volltextzugriff (PDF)

Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: a systematic review and an exploratory meta-analysis

European journal of surgical oncology, 2016-07, Vol.42 (7), p.919-925

2016

Volltextzugriff (PDF)

More on sunitinib 2 weeks on/1 week off schedule: the Rainbow analysis

Annals of oncology, 2016-01, Vol.27 (1), p.202-203

2016

Volltextzugriff (PDF)

Subcutaneous versus intravenous nivolumab for renal cell carcinoma

Annals of oncology, 2024-09

2024

Volltextzugriff (PDF)

Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy

Clinical & translational oncology, 2020-11, Vol.22 (11), p.2130-2135

2020

Volltextzugriff (PDF)

Malignant hypercalcemia

Current medicinal chemistry, 2011-08, Vol.18 (23), p.3462-3467

2011

Volltextzugriff (PDF)

Patient Reported Outcomes, Paternity, Relationship, and Fertility in Testicular Cancer Survivors: Results from a Prospective Observational Single Institution Trial

Patient preference and adherence, 2022-01, Vol.16, p.3393-3403

2022

Volltextzugriff (PDF)

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

ESMO open, 2021-06, Vol.6 (3), p.100118-100118, Article 100118

2021

Volltextzugriff (PDF)

Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas

Current medicinal chemistry, 2013-02, Vol.20 (5), p.613-620

2013

Volltextzugriff (PDF)

Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study

Annals of oncology, 2013-02, Vol.24 (2), p.336-342

2013

Volltextzugriff (PDF)

Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program

ESMO open, 2022-12, Vol.7 (6), p.100634, Article 100634

2022

Volltextzugriff (PDF)

Isolated Limb Perfusion for the Management Limb Threatening Soft Tissue Sarcomas: The Role of Histological Type on Clinical Outcomes

European journal of surgical oncology, 2017-02, Vol.43 (2), p.401-406

2017

Volltextzugriff (PDF)

CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure

Annals of oncology, 2017-10, Vol.28, p.vi17-vi17

2017

Volltextzugriff (PDF)

Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: A multicenter retrospective analysis

European journal of cancer (1990), 2017-02, Vol.72, p.S190-S190

2017

Volltextzugriff (PDF)

2603 Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)

European journal of cancer (1990), 2015-09, Vol.51, p.S512-S513

2015

Volltextzugriff (PDF)

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

The New England journal of medicine, 2023-05, Vol.388 (19), p.1767-1778

2023

Volltextzugriff (PDF)

1604P Aggregated analysis of treatment and survival outcome of all metastatic renal cell carcinoma patients treated from 2014 to 2018 in the Veneto region, Italy

Annals of oncology, 2020-09, Vol.31, p.S966-S967

2020

Volltextzugriff (PDF)

1655P Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study

Annals of oncology, 2024-09, Vol.35, p.S998-S998

2024

Volltextzugriff (PDF)

1691P Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients (pts) with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Updated efficacy and safety results from CheckMate 67T

Annals of oncology, 2024-09, Vol.35, p.S1013-S1014

2024

Volltextzugriff (PDF)

1984P Sex differences in anticancer treatment delivery and toxicity in patients with sarcoma in a reference center

Annals of oncology, 2023-10, Vol.34, p.S1058-S1058

2023

Volltextzugriff (PDF)

1895P Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)

Annals of oncology, 2023-10, Vol.34, p.S1020-S1020

2023

Volltextzugriff (PDF)

1901P Specific dynamic changes of peripheral blood immune profile (PBIP) associate with clinical response to nivolumab (NIVO) in patients (pts) with metastatic renal cell carcinoma (mRCC): The I-RENE trial (meet-URO 8)

Annals of oncology, 2023-10, Vol.34, p.S1022-S1023

2023

Volltextzugriff (PDF)

Glycosaminoglycan Profiling in Patients’ Plasma and Urine Predicts the Occurrence of Metastatic Clear Cell Renal Cell Carcinoma

Cell reports (Cambridge), 2016-05, Vol.15 (8), p.1822-1836

2016

Volltextzugriff (PDF)

1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study

Annals of oncology, 2022-09, Vol.33, p.S1221-S1222

2022

Volltextzugriff (PDF)

1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)

Annals of oncology, 2022-09, Vol.33, p.S1214-S1215

2022

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(71)

Publikationsform

Artikel
(75)
Tagungsberichte
(1)

Sprache

Englisch
(76)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(26)
Science & Technology
(26)
Oncology
(18)
Humans
(14)
Female
(7)
Immunotherapy
(7)
Renal Cell Carcinoma
(6)
Hematology, Oncology And Palliative Medicine
(5)
Metastasis
(5)
Original Research
(5)
Urothelial Carcinoma
(5)
Aged
(4)
Cancer
(4)
Carcinoma, Renal Cell - Drug Therapy
(4)
Chemotherapy
(4)
Kidney Neoplasms - Drug Therapy
(4)
Male
(4)
Medicine
(4)
Medicine & Public Health
(4)
Patients
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Treatment of estrogen receptor-positive breast cancer

Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: a systematic review and an exploratory meta-analysis

More on sunitinib 2 weeks on/1 week off schedule: the Rainbow analysis

Subcutaneous versus intravenous nivolumab for renal cell carcinoma

Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy

Malignant hypercalcemia

Patient Reported Outcomes, Paternity, Relationship, and Fertility in Testicular Cancer Survivors: Results from a Prospective Observational Single Institution Trial

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas

Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study

Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program

Isolated Limb Perfusion for the Management Limb Threatening Soft Tissue Sarcomas: The Role of Histological Type on Clinical Outcomes

CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure

Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: A multicenter retrospective analysis

2603 Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

1604P Aggregated analysis of treatment and survival outcome of all metastatic renal cell carcinoma patients treated from 2014 to 2018 in the Veneto region, Italy

1655P Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study

1691P Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients (pts) with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Updated efficacy and safety results from CheckMate 67T

1984P Sex differences in anticancer treatment delivery and toxicity in patients with sarcoma in a reference center

1895P Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)

1901P Specific dynamic changes of peripheral blood immune profile (PBIP) associate with clinical response to nivolumab (NIVO) in patients (pts) with metastatic renal cell carcinoma (mRCC): The I-RENE trial (meet-URO 8)

Glycosaminoglycan Profiling in Patients’ Plasma and Urine Predicts the Occurrence of Metastatic Clear Cell Renal Cell Carcinoma

1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study

1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)

Suchergebnisse filtern